TAMI-52. G-CSF SECRETED BY EPIGENETICALLY REPROGRAMMED MUTANT IDH1 GLIOMA STEM CELLS, REVERSES THE MYELOID CELLS’-MEDIATED IMMUNOSUPPRESSIVE TUMOR MICROENVIRONMENT

Mutation in isocitrate dehydrogenase (mIDH) is the main genetic lesion that defines clinical glioma subtypes and prognosis. This gain of function mutation is associated with the production of the oncometabolite, R-2-hydroxyglutarate, that inhibits α-ketoglutarate dependent enzymes such as TET2 and t...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Neuro Oncol
Main Authors: Alghamri, Mahmoud, Avvari, Ruthvik, Thalla, Rohit, Zhang, Li, Ventosa, Maria, Taher, Ayman, Núñez, Felipe, Heth, Jason, Orringer, Daniel, Lowenstein, Pedro, Castro, Maria
Formato: Artigo
Idioma:Inglês
Publicado: Oxford University Press 2020
Assuntos:
Tumor Microenvironment/Angiogenesis/Metabolism/Invasion
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7651463/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.939
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares